Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$62.84
+2.2%
$64.48
$42.52
▼
$68.64
$125.63B0.2310.10 million shs10.03 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.81
+0.5%
$45.72
$35.12
▼
$64.16
$172.44B0.7412.68 million shs9.92 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.68
+0.9%
$27.05
$23.61
▼
$29.21
$161.93B0.3432.22 million shs27.75 million shs
UCB SA stock logo
UCBJY
UCB
$122.64
+1.6%
$127.24
$115.20
▼
$168.76
$45.63B0.4546,943 shs28,579 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+2.11%-0.12%-7.15%+9.39%+42.20%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+0.54%-10.23%-17.82%-19.16%-33.97%
Pfizer Inc. stock logo
PFE
Pfizer
+0.94%+3.89%+1.22%+18.13%+19.16%
UCB SA stock logo
UCBJY
UCB
+1.62%+2.55%-4.55%-16.51%+2.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$62.84
+2.2%
$64.48
$42.52
▼
$68.64
$125.63B0.2310.10 million shs10.03 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.81
+0.5%
$45.72
$35.12
▼
$64.16
$172.44B0.7412.68 million shs9.92 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.68
+0.9%
$27.05
$23.61
▼
$29.21
$161.93B0.3432.22 million shs27.75 million shs
UCB SA stock logo
UCBJY
UCB
$122.64
+1.6%
$127.24
$115.20
▼
$168.76
$45.63B0.4546,943 shs28,579 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+2.11%-0.12%-7.15%+9.39%+42.20%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+0.54%-10.23%-17.82%-19.16%-33.97%
Pfizer Inc. stock logo
PFE
Pfizer
+0.94%+3.89%+1.22%+18.13%+19.16%
UCB SA stock logo
UCBJY
UCB
+1.62%+2.55%-4.55%-16.51%+2.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.62
Moderate Buy$67.066.70% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.11
Hold$64.9467.31% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.39-1.00% Downside
UCB SA stock logo
UCBJY
UCB
2.50
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest UCBJY, NVO, PFE, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral$63.00
9/23/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHold ➝ Strong-Buy
9/16/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingOverweight$75.00 ➝ $82.00
9/16/2026
UCB SA stock logo
UCBJY
UCB
DowngradeStrong-Buy ➝ Hold
9/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetHold$28.00 ➝ $30.00
9/10/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingHold
9/10/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingHold$60.00 ➝ $65.00
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-) ➝ Hold (C)
8/27/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHold ➝ Sell
8/18/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHold (C+) ➝ Buy (B-)
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C) ➝ Hold (C-)
(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.66$8.31 per share7.56$9.09 per share6.91
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.70$4.71 per share8.24$6.58 per share5.90
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.61$4.44 per share6.46$15.26 per share1.88
UCB SA stock logo
UCBJY
UCB
$8.76B5.29N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5413.849.730.2918.87%66.90%14.74%10/29/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.099.4911.351.2635.36%58.61%20.91%11/4/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7637.739.751.916.80%19.63%8.46%11/3/2026 (Estimated)
UCB SA stock logo
UCBJY
UCB
$1.76BN/AN/A15.581.00N/AN/AN/AN/A

Latest UCBJY, NVO, PFE, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.01%+1.61%55.51%17 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.822.11%+21.74%20.05%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.00%-13.20%226.32%16 Years
UCB SA stock logo
UCBJY
UCB
$0.530.43%N/AN/AN/A

Latest UCBJY, NVO, PFE, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.633.97%10/2/202610/2/202611/2/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
UCB SA stock logo
UCBJY
UCB
0.20
1.38
1.04

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
UCB SA stock logo
UCBJY
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
UCB SA stock logo
UCBJY
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
UCB SA stock logo
UCBJY
UCB
10,117378.04 millionN/ANot Optionable

Recent News About These Companies

UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
UCB (UCBJY) Upgraded to Buy: Here's Why
UCB ADR (UCBJY) Ratios
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB ADR Stock Price History

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$62.84 +1.34 (+2.19%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$62.84 0.00 (-0.01%)
As of 09/25/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$38.81 +0.19 (+0.50%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$38.80 -0.02 (-0.04%)
As of 09/25/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$28.68 +0.27 (+0.93%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$28.67 0.00 (-0.02%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UCB stock logo

UCB OTCMKTS:UCBJY

$122.64 +1.95 (+1.62%)
As of 09/25/2026 03:56 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.